[go: up one dir, main page]

MX2018007377A - Composicion de acido hialuronico para inyecciones en el pene. - Google Patents

Composicion de acido hialuronico para inyecciones en el pene.

Info

Publication number
MX2018007377A
MX2018007377A MX2018007377A MX2018007377A MX2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A MX 2018007377 A MX2018007377 A MX 2018007377A
Authority
MX
Mexico
Prior art keywords
hyaluronic acid
acid composition
relates
composition
penile
Prior art date
Application number
MX2018007377A
Other languages
English (en)
Inventor
Diacakis Richard
Original Assignee
Vivacy Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivacy Int Sa filed Critical Vivacy Int Sa
Publication of MX2018007377A publication Critical patent/MX2018007377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al campo del agrandamiento del pene y a las composiciones de ácido hialurónico para su use en la forma de inyecciones en el pene. La misma también se refiere a la penoplastia que usa una inyección de ácido hialurónico. La misma se refiere rads particularmente a una composición que comprende al menos un -ácido hialurónico reticulado, usada en el tratamiento del síndrome de vestidor y caracterizada porque se administra en una dosis de al menos 0.15 mlicm2, y porque la composición se administra repetidamente, con una primera administración que es seguida por n administración(es) subsiguiente(s) espaciadas por un intervalo de tiempo entre 6 y 20 meses, con n > 1.
MX2018007377A 2015-12-16 2016-12-16 Composicion de acido hialuronico para inyecciones en el pene. MX2018007377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/080110 WO2017102001A1 (fr) 2015-12-16 2015-12-16 Composition d'acide hyaluronique pour injections peniennes
PCT/EP2016/081624 WO2017103241A1 (fr) 2015-12-16 2016-12-16 Composition d'acide hyaluronique pour injections peniennes

Publications (1)

Publication Number Publication Date
MX2018007377A true MX2018007377A (es) 2018-11-09

Family

ID=54979674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007377A MX2018007377A (es) 2015-12-16 2016-12-16 Composicion de acido hialuronico para inyecciones en el pene.

Country Status (7)

Country Link
US (2) US20180361019A1 (es)
EP (1) EP3389675A1 (es)
JP (1) JP2019500429A (es)
KR (1) KR20180102097A (es)
CN (1) CN109789157A (es)
MX (1) MX2018007377A (es)
WO (2) WO2017102001A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3373832T (pt) * 2015-11-10 2024-09-02 Paul E Perito Composição para utilização num método terapêutico para o aumento não cirúrgico da circunferência do pénis
WO2020095079A1 (fr) * 2018-11-06 2020-05-14 Kylane Laboratoires Sa Composition injectable contenant de l'acide hyaluronique pour des applications au niveau du corps

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200080A1 (de) 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
GB9902412D0 (en) 1999-02-03 1999-03-24 Fermentech Med Ltd Process
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
CN1787824A (zh) * 2003-06-25 2006-06-14 有限会社循环器研究所 性交功能改善用外用制剂
CN1287870C (zh) * 2003-09-17 2006-12-06 启东致远生物科技有限公司 阴茎增长植入物
FR2895907B1 (fr) 2006-01-06 2012-06-01 Anteis Sa Gel viscoelastique a usage dermatologique
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2951368B1 (fr) 2009-10-16 2012-11-16 Jacques Derhy Implants volumetriques cosmetiques du penis
FR2983483B1 (fr) 2011-12-02 2014-11-14 Vivacy Lab Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) * 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
EP2764847A1 (en) 2013-02-08 2014-08-13 Kirch Urologie B.V. Penile augmentation

Also Published As

Publication number Publication date
EP3389675A1 (fr) 2018-10-24
WO2017102001A1 (fr) 2017-06-22
KR20180102097A (ko) 2018-09-14
US20200397944A1 (en) 2020-12-24
US20180361019A1 (en) 2018-12-20
JP2019500429A (ja) 2019-01-10
CN109789157A (zh) 2019-05-21
WO2017103241A1 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
PE20190205A1 (es) Uso de inhibidores de miostatina y terapias de combinacion
PH12017501774A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MX2019012884A (es) Terapia de combinacion.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
MX2017008569A (es) Derivados de glucagon con estabilidad mejorada.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
BR112018012439A2 (pt) ?composição compreendendo, pelo menos, um ácido hialurônico reticulado, utilizada no tratamento da síndrome do vestiário?
MX349193B (es) Capsula con contenido liquido con un antiinflamatorio.
MY203965A (en) Injectable formulations of paracetamol
ZA202202673B (en) Methods and compositions for treating endometriosis
EA201700347A2 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
BR112022004723A2 (pt) Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração